STOCK TITAN

Immatics N.V - IMTX STOCK NEWS

Welcome to our dedicated page for Immatics N.V news (Ticker: IMTX), a resource for investors and traders seeking the latest updates and insights on Immatics N.V stock.

Immatics N.V. (IMTX) is a clinical-stage biopharmaceutical leader developing T-cell redirecting immunotherapies for cancer treatment. This news hub provides investors and researchers with timely updates on groundbreaking therapies targeting solid and liquid tumors through proprietary platforms like Xpresient® and TCER® molecules.

Access consolidated coverage of press releases, clinical trial milestones, and strategic partnerships. Track developments in adoptive cell therapies and bispecific TCR molecules designed to enhance precision oncology outcomes. Our repository ensures you never miss critical updates about FDA interactions, collaborative research advancements, or pipeline expansions.

Key content categories include clinical program updates, partnership announcements with major industry players, financial disclosures, and scientific presentations. All materials are vetted for relevance to investment analysis and therapeutic innovation.

Bookmark this page for streamlined access to Immatics' latest achievements in immuno-oncology. Check regularly for authoritative reporting on their mission to redefine cancer treatment through engineered T-cell therapies.

Rhea-AI Summary

Immatics and Bristol Myers Squibb have expanded their strategic collaboration to develop allogeneic TCR-T and CAR-T therapies. Immatics will receive an upfront payment of $60 million, with additional milestone payments of up to $700 million for each program, along with tiered royalties. The partnership will leverage Immatics’ ACTallo® platform and Bristol Myers Squibb’s oncology expertise, focusing on multiple programs. Additionally, an autologous TCR-T target will be added under their existing 2019 agreement, granting Immatics a further $20 million upfront.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.18%
Tags
none
-
Rhea-AI Summary

Immatics N.V. (NASDAQ: IMTX) announced the initiation of a Phase 1b dose expansion cohort for its IMA203 TCR-T therapy in combination with Bristol Myers Squibb’s nivolumab, targeting solid tumors. This follows positive interim results from the Phase 1a trial. The study aims to assess safety and anti-tumor activity across up to 18 patients at 10 U.S. and German sites. Data read-outs for this combination and other ongoing studies are expected by year-end 2022, which is crucial for future clinical development.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.83%
Tags
none
-
Rhea-AI Summary

Immatics has launched a Phase 1 clinical trial of IMA401, a T cell engaging receptor (TCER®) aimed at treating patients with recurrent and/or refractory solid tumors. The trial, which has begun patient enrollment at its first site in Germany, seeks to evaluate the safety, tolerability, and initial anti-tumor efficacy of IMA401. This candidate targets MAGEA4/8 peptides and will be developed in collaboration with Bristol Myers Squibb, emphasizing Immatics' commitment to advancing innovative immunotherapies.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3%
Tags
Rhea-AI Summary

Immatics (NASDAQ: IMTX) announced positive interim results for its IMA203 TCR-T candidate, showing a 50% objective response rate in a Phase 1a trial targeting PRAME across multiple solid tumors. The company is set to initiate multiple Phase 1b expansion cohorts in Q2 2022, including monotherapy and combination therapies. Additionally, a global licensing agreement with Bristol Myers Squibb provides Immatics with a $150 million upfront payment and up to $770 million in potential milestone payments. As of December 31, 2021, cash reserves totaled $164 million, ensuring operational funding through 2024.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.76%
Tags
-
Rhea-AI Summary

Bristol Myers Squibb (NYSE:BMY) reported Q4 revenues of $12.0 billion, an 8% increase driven by robust sales of Eliquis and immuno-oncology products. Full-year revenues reached $46.4 billion, up 9%. Q4 earnings per share (EPS) stood at $1.07 (GAAP) and $1.83 (non-GAAP), with annual EPS at $3.12 and $7.51 respectively. The company announced a $15 billion share repurchase authorization and provided 2022 guidance, predicting $47 billion in revenues. The outlook includes expected growth from new products and a reduction in operating expenses.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.32%
Tags
-
Rhea-AI Summary

Bristol Myers Squibb (NYSE:BMY) has reported fourth quarter revenues of $12.0 billion, marking an 8% increase year-over-year, and full-year revenues of $46.4 billion. The fourth quarter earnings per share (EPS) stand at $1.07 (GAAP) and $1.83 (non-GAAP), with full-year EPS at $3.12 and $7.51 respectively, reflecting a 17% growth in non-GAAP EPS. The company has authorized a $15 billion share repurchase initiative and announced a $5 billion accelerated share repurchase agreement for Q1 2022. Guidance for 2022 includes projected revenues of approximately $47 billion.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.32%
Tags
Rhea-AI Summary

Immatics has secured a significant collaboration with Bristol Myers Squibb to develop the TCR bispecific candidate IMA401. The agreement entails an upfront payment of $150 million, with potential milestone payments totaling up to $770 million and double-digit royalties on net sales. IMA401 targets the MAGEA4/8 antigen prevalent in solid tumors and has demonstrated promising anti-tumor activity in preclinical studies. Clinical trials are expected to start in the first half of 2022.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.88%
Tags
none
-
Rhea-AI Summary

Bristol Myers Squibb (BMY) has secured a global exclusive license to Immatics' (IMTX) TCR bispecific program IMA401. This strategic collaboration involves an upfront payment of $150 million to Immatics, alongside potential milestone payments totaling $770 million and tiered double-digit royalties on net sales. IMA401 targets MAGEA4/8 antigens prevalent in solid tumors and has shown promising preclinical anti-tumor activity. The clinical trial is expected to start in the first half of 2022, enhancing both companies' oncology portfolios.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.88%
Tags
none
-
Rhea-AI Summary

Immatics reported a positive update on its ACTengine® IMA203 trial targeting PRAME, showcasing a 94% disease control rate in evaluable patients and 50% achieving objective responses. The company plans to initiate three expansion cohorts for IMA203, including monotherapy and combinations with checkpoint inhibitors. Financially, cash reserves stand at $200.6 million as of September 30, 2021, though the company recorded a net loss of €27.2 million for Q3 2021, a decrease from a significant loss in Q3 2020. This news positions Immatics for potential growth in immunotherapy.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.18%
Tags
Rhea-AI Summary

Immatics N.V. (NASDAQ: IMTX) has reported interim clinical data from its ongoing Phase 1a trial of ACTengine® IMA203, showing a 50% objective response rate (8/16 patients) across various solid cancers. Notably, 62% responded to higher dose levels. The therapy was well-tolerated, with manageable adverse events and no significant toxicities. Key findings indicate promising tumor infiltration and T cell persistence. The data will be presented at the SITC Annual Meeting on November 13, 2021, highlighting the potential of IMA203 in treating advanced solid cancers.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-13.92%
Tags
Immatics N.V

NYSE:IMTX

IMTX Rankings

IMTX Stock Data

517.80M
79.12M
22.17%
87.52%
7.11%
Biotechnology
Healthcare
Link
Germany
Tübingen